Prelude Therapeutics Incorporated

3.68 USD
-0.10 (-2.65%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Prelude Therapeutics Incorporated stock is up 15.36% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 February’s closed higher than January. 0% of analysts rate it a buy.

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

  • HC Wainwright & Co.
    Tue Feb 20, 09:01